Skip to main content

Cutaneous & COVID News

A survey of patients with psoriasis found that a majority of respondents stated that they would stop their biologic or reduce their dosage during the pandemic, illustrating a critical need for dermatologists to discuss the relationship between COVID-19 and immunomodulating therapies with their patients.
The National Psoriasis Foundation released guidance on vaccination with the new SARS-CoV-2 vaccine for patients with psoriasis.
Analysis from the COVID-19 Dermatology Registry revealed that some patients who develop cutaneous symptoms of the disease become “long haulers” with persistent skin symptoms lasting as long as 150 days. Data were presented in a late-breaking abstract by principal investigator Esther Freeman, MD, PhD, at EADV Virtual on October 29, 2020.
Data from an international registry showed that patients with psoriasis who received a biologic were less likely to be hospitalized vs patients who received a non-biologic systemic therapy. This data from the PsoProtect registry were published in the Journal of Allergy and Clinical Immunology.
Researchers assessed the timing of testing for COVID-19 in relation to cutaneous manifestations using data from an international registry.
The 18-physician task force, led by Joel M. Gelfand, MD, MSCE, and Christopher T. Ritchlin, MD, MPH, used a Delphi process to determine 22 guidance statements for care during the COVID-19 pandemic.
A group of researchers out of Henry Ford Health System in Detroit, MI, found that immunosuppressive therapies were not associated with a significantly greater risk of severe COVID-19. The results of their study were published online in Journal of the American Academy of Dermatology.
Findings from two European studies published in JAMA Dermatology assessed the potential association between chilblains and COVID-2019.
Back to Top